company background image
HXL

HeximaASX:HXL Stock Report

Market Cap

AU$47.8m

7D

-3.9%

1Y

n/a

Updated

18 Oct, 2021

Data

Company Financials
HXL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

HXL Overview

Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics.

Price History & Performance

Summary of all time highs, changes and price drops for Hexima
Historical stock prices
Current Share PriceAU$0.36
52 Week HighAU$0.14
52 Week LowAU$0.50
Beta0
1 Month Change-1.35%
3 Month Change78.05%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO87.18%

Recent News & Updates

Sep 06
Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn Situation

Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

HXLAU BiotechsAU Market
7D-3.9%2.3%0.9%
1Yn/a1.5%20.2%

Return vs Industry: Insufficient data to determine how HXL performed against the Australian Biotechs industry.

Return vs Market: Insufficient data to determine how HXL performed against the Australian Market.

Price Volatility

Is HXL's price volatile compared to industry and market?
HXL volatility
HXL Beta0
Industry Beta1.61
Market Beta1

Stable Share Price: HXL is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: HXL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1997n/aMichael D. Aldridgehttps://www.hexima.com.au

Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company’s lead drug candidate is the plant defensin, pezadeftide, which is in phase IIb clinical trials for the treatment of fungal toenail infections in Australia and New Zealand. The company was incorporated in 1997 and is headquartered in Melbourne, Australia.

Hexima Fundamentals Summary

How do Hexima's earnings and revenue compare to its market cap?
HXL fundamental statistics
Market CapAU$47.76m
Earnings (TTM)-AU$6.87m
Revenue (TTM)AU$4.08m

11.7x

P/S Ratio

-6.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HXL income statement (TTM)
RevenueAU$4.08m
Cost of RevenueAU$208.58k
Gross ProfitAU$3.87m
ExpensesAU$10.75m
Earnings-AU$6.87m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.053
Gross Margin94.89%
Net Profit Margin-168.39%
Debt/Equity Ratio1.1%

How did HXL perform over the long term?

See historical performance and comparison

Valuation

Is Hexima undervalued compared to its fair value and its price relative to the market?

15.69x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HXL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HXL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HXL is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: HXL is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HXL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HXL is overvalued based on its PB Ratio (15.7x) compared to the AU Biotechs industry average (4.9x).


Future Growth

How is Hexima forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hexima has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Hexima performed over the past 5 years?

-26.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HXL is currently unprofitable.

Growing Profit Margin: HXL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HXL is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.

Accelerating Growth: Unable to compare HXL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HXL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: HXL has a negative Return on Equity (-225.69%), as it is currently unprofitable.


Financial Health

How is Hexima's financial position?


Financial Position Analysis

Short Term Liabilities: HXL's short term assets (A$7.4M) exceed its short term liabilities (A$3.9M).

Long Term Liabilities: HXL's short term assets (A$7.4M) exceed its long term liabilities (A$1.6M).


Debt to Equity History and Analysis

Debt Level: HXL's debt to equity ratio (1.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if HXL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HXL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: HXL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.7% each year


Dividend

What is Hexima current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HXL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HXL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HXL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HXL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HXL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Michael D. Aldridge (54 yo)

1

Tenure

AU$876,272

Compensation

Mr. Michael D. A. Aldridge, B.Sc (Hons)., MApFin, serves as Managing Director and Chief Executive Officer at Hexima Limited since October 1, 2020 and serves as its Executive Director since May 21, 2019. He...


CEO Compensation Analysis

Compensation vs Market: Michael D.'s total compensation ($USD650.39K) is above average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: Michael D.'s compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: HXL's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: HXL's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: HXL only recently listed within the past 12 months.


Top Shareholders

Company Information

Hexima Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Hexima Limited
  • Ticker: HXL
  • Exchange: ASX
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$47.763m
  • Shares outstanding: 130.86m
  • Website: https://www.hexima.com.au

Location

  • Hexima Limited
  • La Trobe Institute for Molecular Science
  • Level 4,LIMS 2
  • Melbourne
  • Victoria
  • 3086
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 15:28
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.